Hypernil: Advanced Blood Pressure Control for Lasting Cardiovascular Health
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 60 | $1.14 | $68.28 (0%) | 🛒 Add to cart |
| 90 | $0.96 | $102.41 $86.35 (16%) | 🛒 Add to cart |
| 120 | $0.87 | $136.55 $104.42 (24%) | 🛒 Add to cart |
| 180 | $0.78 | $204.83 $140.57 (31%) | 🛒 Add to cart |
| 270 | $0.72 | $307.24 $194.79 (37%) | 🛒 Add to cart |
| 360 | $0.69
Best per tab | $409.66 $249.01 (39%) | 🛒 Add to cart |
Hypernil is a next-generation antihypertensive medication designed for precise, sustained management of elevated blood pressure. Combining a potent active ingredient with advanced delivery technology, it offers clinicians a reliable tool for achieving target blood pressure goals in diverse patient populations. Its well-studied pharmacokinetic profile ensures consistent 24-hour coverage, reducing variability and supporting long-term adherence. Trusted in therapeutic regimens worldwide, Hypernil represents a cornerstone in modern cardiovascular risk reduction strategies.
Features
- Contains amlodipine besylate as the active pharmaceutical ingredient
- Available in 5 mg and 10 mg film-coated tablets
- Once-daily dosing regimen for consistent therapeutic coverage
- Bioavailability of approximately 64-90% with minimal food interaction
- Plasma protein binding exceeds 95%
- Onset of action within 6-12 hours; full therapeutic effect achieved in 7-14 days
- Elimination half-life of 30-50 hours supports steady-state concentration
- Manufactured under cGMP conditions with batch-to-batch consistency
Benefits
- Provides smooth, sustained blood pressure reduction over 24 hours, minimizing early morning surge risk
- Reduces peripheral vascular resistance through selective action on vascular smooth muscle
- Lowers overall cardiovascular event risk through consistent hypertension management
- Demonstrates excellent tolerability with a low incidence of reflex tachycardia
- Supports patient adherence through simple once-daily dosing
- May be used as monotherapy or in combination with other antihypertensive agents
Common use
Hypernil is primarily indicated for the treatment of hypertension, either as monotherapy or in combination with other blood pressure-lowering medications. It is also used in the management of chronic stable angina and vasospastic angina. The medication is particularly valuable in patients requiring consistent diurnal coverage and those with comorbidities where calcium channel blockers are preferred. Clinical studies support its use across various demographic groups, including elderly patients and those with renal impairment, though dosage adjustments may be necessary.
Dosage and direction
The recommended initial dosage for most adults with hypertension is 5 mg taken orally once daily. Dosage may be increased to a maximum of 10 mg daily based on therapeutic response and tolerability. Administration may occur with or without food, though consistency in timing is recommended. Tablets should be swallowed whole with a glass of water; they should not be crushed or chewed. For elderly patients or those with hepatic impairment, initiation at 2.5 mg daily is advised. Therapeutic effect is typically observed within one to two weeks, with maximal effects achieved after four weeks. Regular blood pressure monitoring is essential during dosage titration.
Precautions
Patients should be cautioned about possible dizziness or lightheadedness, particularly during initial therapy or dosage increases. Peripheral edema may occur and is typically dose-dependent. Use with caution in patients with severe aortic stenosis due to reduced afterload compensation. Hepatic impairment may require dosage adjustment as metabolism occurs primarily in the liver. Patients should avoid grapefruit juice consumption as it may increase bioavailability. Abrupt discontinuation should be avoided; gradual tapering is recommended under medical supervision. Regular monitoring of blood pressure, heart rate, and potential signs of heart failure is advised during treatment.
Contraindications
Hypernil is contraindicated in patients with known hypersensitivity to amlodipine or any component of the formulation. It should not be used in patients with severe hypotension (systolic pressure <90 mmHg). Contraindicated in patients with cardiogenic shock or acute myocardial infarction with pulmonary congestion documented by x-ray. Not recommended during pregnancy unless potential benefit justifies potential risk to fetus. Should be avoided in breastfeeding women due to secretion in human milk. Use is contraindicated in combination with strong CYP3A4 inhibitors in patients with hepatic impairment.
Possible side effects
Common adverse reactions (≥2%) include peripheral edema (8.3%), headache (7.3%), fatigue (4.5%), nausea (2.9%), and flushing (2.6%). Less frequent side effects (<2%) include palpitations, dizziness, somnolence, abdominal pain, and rash. Rare but serious adverse effects include symptomatic hypotension, worsening angina, myocardial infarction, and arrhythmias. Cases of gingival hyperplasia have been reported with long-term use. Laboratory abnormalities may include transient elevations in liver enzymes. Most side effects are mild to moderate and often diminish with continued therapy.
Drug interaction
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) may increase amlodipine concentrations. Simvastatin coadministration may increase simvastatin exposure. Concurrent use with other antihypertensives may potentiate blood pressure lowering effects. Use with sildenafil or other PDE5 inhibitors may result in additive blood pressure reduction. Calcium supplements may reduce the effectiveness of calcium channel blockers. Cyclosporine may increase amlodipine exposure through CYP3A4 inhibition. Monitor digoxin levels when coadministered due to possible increase in digoxin concentration.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining therapeutic blood levels. Setting a daily reminder or using a pill organizer can help prevent missed doses. If multiple doses are missed, patients should contact their healthcare provider for guidance.
Overdose
Overdose may manifest as pronounced hypotension with possible reflex tachycardia. Bradycardia may occur in some cases. Symptoms might include dizziness, lightheadedness, and syncope. Supportive measures should include elevation of lower extremities and judicious fluid administration. Activated charcoal may be administered if ingestion was recent. Hemodynamic monitoring is essential. Intravenous calcium gluconate may help reverse effects of calcium channel blockade. Vasopressors such as dopamine or norepinephrine may be required for refractory hypotension. Dialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use if the blister pack is damaged or tablets show signs of deterioration. Do not transfer tablets to other containers. Discard any unused medication after the expiration date printed on the packaging. Do not flush medications down the toilet or pour down the drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare professionals should exercise their own professional judgment when considering the use of this product. Patients should not make changes to their medication regimen without consulting their healthcare provider. The complete prescribing information should be consulted before initiating therapy. This product is available by prescription only and should be used under appropriate medical supervision.
Reviews
Clinical trials demonstrate Hypernil achieves target blood pressure in 75-85% of patients with mild to moderate hypertension. A meta-analysis of 12 studies showed consistent 24-hour ambulatory blood pressure control with mean reductions of 12-15 mmHg systolic and 8-10 mmHg diastolic. Long-term extension studies indicate maintained efficacy over 52 weeks with stable safety profile. Real-world evidence from post-marketing surveillance confirms the clinical trial findings, with particularly positive outcomes in elderly hypertensive patients. Patient satisfaction surveys indicate high adherence rates due to once-daily dosing and generally favorable side effect profile compared to other antihypertensive classes.